Neurology

Tau proteins
#Asceneuron #Ferrer #License agreement #Neurodegenerative disorders #Neurology #Orphan drugs #Tau protein

Ferrer secures worldwide rights to PSP drug

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.  The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone… Read More

#Business & Investment #News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Brain #Gut microbiome #Mouse models #Neurology #Neuroscience

Mouse study findings suggest new approach to treating Alzheimer’s 

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.  Context   Researchers at Washington University School of Medicine in St Louis showed that… Read More

#News

Human neurone
#Biosciences #Genetic diseases #Ion channels #Neurology #Neuroscience #Rare disease #Therapeutics

Ion channel modulators for ultra-rare genetic disorder 

Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not-for-profit organisation focused on the development of a treatment for an ultra-rare genetic disorder, have entered a collaboration to progress a hit identification research project for small molecule modulators of the potassium… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Collaboration #Genetics / genomics #Neurodevelopmental disorders #Neurology #Precision medicine #Rare disease

Partnership hopes to advance precision drug development

A new partnership between industry and three rare disease foundations has formed with the goal of accelerating the development of precision drugs to treat rare neurodevelopmental disorders.  AI-driven genomics company Genomenon will partner with COMBINEDBrain, SynGAP Research Fund, and SLC-6A1 Connect and their pharma partners to deliver… Read More

#News

Brain inflammation
#Alzheimer's #Brain disease #Neurodegenerative disorders #Neuroinflammation #Neurology #Parkinson's

Covid-19 triggers inflammation in the brain

Research led by The University of Queensland has found that Covid-19 activates the same inflammatory response in the brain as Parkinson’s disease.  The discovery identified a potential future risk for neurodegenerative conditions in people who have had Covid-19, but also a possible treatment.  The UQ… Read More

#Covid-19 #News

Patient reported outcomes
#Biomarkers #Mental health #Neurodegenerative disorders #Neurology #Neuroscience #Psychiatry

The rise of digital biomarkers in neuroscience drug development 

Listen to this article on the DDW Podcast: Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Ask Dr J Mark Treherne, Dr Jenny Barnett and Dr Paula Moran.  Increasingly, digital biomarkers are becoming more effectively used in the discovery and… Read More

#Editor's Choice #Exclusive Content

#Appointment #Biopharma #Neurology

TikoMed appoints new members to Board of Directors

Biopharmaceutical company TikoMed has announced two new appointments to its Board of Directors as the company focuses on its ILB drug programme. TikoMed has appointed Tara Heitner and Pete Zorn to its Board of Directors. Tara Heitner has more than 15 years of experience in the biopharmaceutical industry and has… Read More

#Business & Investment #News

#Alzheimer's #Collaboration #Neurology #US

Cerevance teams up with Merck (MSD) on Alzheimer’s project  

Drug discovery and development company Cerevance has announced a multi-year strategic research collaboration with Merck (MSD), focused on identifying novel targets for Alzheimer’s disease.   Cerevance will receive an upfront payment of $25 million from Merck (MSD) and could receive development and commercial milestone payments of up to… Read More

#News

#Clinical trials #Neurology

Oxeia Biopharmaceuticals encouraged by concussion treatment 

Clinical stage biotech company Oxeia Biopharmaceuticals has announced interim results from a Phase II trial investigating its treatment for concussion.  Oxeia’s OXE103 treatment is targeting concussion in a bid to address underlying neuro-metabolic dysfunction and axonal injury. The company has now completed an interim analysis of its… Read More

#News

#Covid-19 #Drug Discovery 2022 #ELRIG #HIV #Neurology

This week in drug discovery (1-5 August)

News round-up by DDW’s Reece Armstrong for 1-5 August Research paves way for easier brain tumour diagnosis New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas. IFC invests $30 million to improve healthcare in… Read More

#News

#Diagnostics #Neurology #Oncology

Research paves way for easier brain tumour diagnosis  

New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas.  Researchers from the University of Bristol in the UK, developed mathematical models to assess the current use of biomarkers in the detection of glioblastomas… Read More

#News

#Drug discovery #Neurology #Small molecules

Sosei teams up with Abbvie on neurological drug discovery  

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases.   The agreement will see the companies combining their expertise and capabilities in neuroscience to discover and develop small molecules that modulate G protein-coupled… Read More

#News

Human brain
#Biologics / Biotechnology #Clinical trials #Drug discovery #Neurology

Calidi Biotherapeutics gets FDA go-ahead for US trial  

Biotechnology company Calidi Biotherapeutics has announced that a Phase I US clinical trial will use the company’s licensed oncolytic virotherapy platform NeuroNova to deliver an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma.  The phase I physician-sponsored clinical trial will take place at… Read More

#News

#Alzheimer's #Biogen #EIT Health #Neurology

Start-ups win EU-pharma Alzheimer’s contest  

Two start-ups have won a competition organised by EIT Health and pharmaceutical company Biogen which aimed at identifying solutions for Alzheimer’s disease.   French start-up Five Lives and Dutch start-up Neurocase were respectively placed first and second in the ‘neurotechprize’ competition. The winners were announced during a ceremony… Read More

#News